Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    2 (IPSC) Insider Trading Activity

    Healthcare • Biotechnology • 152 employees

    Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

    Total Value

    -$356,547.17

    Total Shares

    -123,255

    Average Trade Value

    -$39,616.35

    Most Active Insider

    Pfeiffenberger Brent

    Total Activity: $350,564

    Largest Single Transaction

    $350,564

    by Pfeiffenberger Brent on Dec 4, 2024

    30-Day Activity

    2 Transactions

    Volume: 1,405 shares
    Value: $1,096

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    SVP Finance Operations
    Officer
    Feb 3, 2025 351 $274 316,796 (-0.1%) Sale
    Chief Operations Officer
    Officer
    Feb 3, 2025 1,054 $822 134,076 (-0.8%) Sale
    President and CEO
    Director, Officer
    Dec 4, 2024 243,447 $350,564 1,227,257 (-19.8%) Payment of Exercise Price
    Chief Operations Officer
    Officer
    Nov 4, 2024 1,033 $1,267 135,130 (-0.8%) Sale
    SVP Finance Operations
    Officer
    Nov 4, 2024 283 $347 317,147 (-0.1%) Sale
    SVP Finance Operations
    Officer
    Nov 1, 2024 16,611 $20,930 317,430 (-5.2%) Payment of Exercise Price
    Chief Finanical Officer
    Officer
    Oct 14, 2024 60,148 $0 60,148 (+100.0%) Grant
    Chief Scientific Officer
    Officer
    Oct 1, 2024 74,376 $10,000 210,806 (+35.3%) Grant
    Director
    Sep 12, 2024 5,000 $7,657 5,000 (+100.0%) Purchase